New drugsAll countries · Checked
New Weight Loss Drugs 2026: What Is Approved and What Is Coming
As of November 20, 2026, two weight loss pills are approved in the US: the Wegovy pill (December 22, 2025) and Foundayo (April 1, 2026). Both are also approved in the UK (June 11 and August 10, 2026). CagriSema, a new weekly injection, is waiting for an FDA decision expected in the fourth quarter of 2026.
What is new in weight loss drugs right now?
Two pills are approved: the Wegovy pill and Foundayo (orforglipron). No new injection has been approved yet.
Approved in the USWegovy pill, Foundayo
Approved in the UKWegovy pill, Foundayo (not on the NHS)
Under FDA reviewCagriSema, decision expected Q4 2026
Based on the FDA, the UK MHRA, the European Medicines Agency and Novo Nordisk.
A new drug still has to fit your budget.
See the cheapest GLP-1 options in the USIn the UK? See weight loss injection prices in the UK.
New drugsPillsResultsSide effectsUKInjectionsPill or injectionPriceFAQ
New weight loss drug
The first new weight loss drug approved in 2026 is Foundayo. The FDA approved it on April 1, 2026, as a tablet taken once a day.
The Wegovy pill came a little earlier. The FDA approved it on December 22, 2025, as the first oral GLP-1 medicine for obesity.
Both are for adults and are used with a reduced-calorie diet and more physical activity. They are approved for people with obesity, or with overweight and at least one weight-related condition.
Among injections, the closest new option is CagriSema, which is still under review. It is covered below.
New weight loss pill
Two pills are approved in the US. Here they are side by side.
Wegovy pill (semaglutide)
Made by Novo Nordisk. It starts at 1.5 mg and moves to 4 mg, 9 mg and 25 mg, a month at each step. The maintenance dose is 25 mg. You take it on an empty stomach with up to 4 oz of water and wait 30 minutes before eating or drinking.
Foundayo (orforglipron)
Made by Eli Lilly. It starts at 0.8 mg, goes to 2.5 mg and 5.5 mg, and can reach 9 mg, 14.5 mg or 17.2 mg, with at least 30 days on each step. You can take it with or without food.
Each pill has its own dosing rules. The full schedules are in Wegovy pill (oral semaglutide) and Foundayo (orforglipron).
How much weight the new pills took off
The numbers below are average results from the trials in each US label. The trials differ in length and design, so they do not compare the two pills head to head.
Average weight change, with placebo for comparison
Wegovy pill, 64 weeks-13.6% (placebo -2.4%)
Foundayo 17.2 mg, 72 weeks-11.1% (placebo -2.1%)
In the Wegovy pill trial, 76.3% of people on the pill lost at least 5% of their body weight, against 31.3% on placebo.
People with type 2 diabetes lose less on average. In the Foundayo diabetes trial, 17.2 mg gave -9.6% over 72 weeks.
These are averages. They do not tell you how much you will lose.
Side effects of the new weight loss pills
For both pills, the most common side effects are stomach problems: nausea, vomiting, diarrhea and constipation.
In the Foundayo label, people on 17.2 mg reported nausea (35%), diarrhea (25%), vomiting (24%) and constipation (24%). On placebo the figures were 10%, 11%, 4% and 9%.
Both pills carry a boxed warning about thyroid C-cell tumors. Neither can be used by anyone with a personal or family history of medullary thyroid cancer, or with multiple endocrine neoplasia syndrome type 2.
The warning comes from rodent studies. Whether it applies to people has not been settled.
New weight loss pill in the UK
The UK regulator, the MHRA, approved the Wegovy pill on June 11, 2026, and Foundayo on August 10, 2026.
Foundayo is licensed for weight management and for type 2 diabetes, and the UK was the first country in Europe to authorise it.
Both pills are for adults with a BMI of 30 or more, or a BMI of 27 to 30 with a weight-related condition. Both need a prescription.
Neither pill is available on the NHS right now. NHS use depends on an evaluation by NICE first. Current NHS rules for injections are in weight loss injections on the NHS.
In the European Union, the EMA's committee recommended approval of Foundayo on October 15, 2026. The next step is a decision by the European Commission.
New meds for weight loss: injections still in the pipeline
CagriSema combines cagrilintide and semaglutide in one weekly injection. Novo Nordisk filed a new drug application with the FDA in December 2025.
An FDA decision is expected in the fourth quarter of 2026. If it is approved, Novo Nordisk plans a US launch in early 2027.
In REDEFINE 1, which followed 3,417 adults without diabetes for 68 weeks, average weight loss was 20.4% on CagriSema against 3.0% on placebo.
CagriSema is not approved in the US, so its safety and effectiveness are not established. More is in CagriSema.
Lilly's retatrutide finished its first large phase 3 trial, TRIUMPH-1, on April 30, 2026, and Lilly reported the results on May 21, 2026. The timeline is in retatrutide FDA approval and release date.
The approval dates for tirzepatide, which is already on the market, are in Mounjaro and Zepbound approval dates. Another candidate is covered in survodutide.
Is a new weight loss pill better than an injection?
Some people prefer a daily pill and some prefer one injection a week. On average weight loss in trials, injections have reached larger numbers.
For example, the 2.4 mg Wegovy injection averaged 14.9% in a 68-week trial, and the Wegovy pill averaged 13.6% in 64 weeks.
The Wegovy pill label explains how to switch. After stopping the 2.4 mg injection, you start the 25 mg pill one week later.
Switching is a decision for you and your prescriber.
New weight loss drugs: generics and price
Prices differ by country, so this page lists none. Foundayo prices in the US are in Foundayo price in the US.
Which GLP-1 medicines have generics is listed in generic GLP-1 drugs. The pills and injections described above are sold under their brand names.
Your insurance changes what you pay. In the US, see GLP-1 without insurance.
New weight loss drug FAQ
Is there an approved weight loss pill?
Yes. The Wegovy pill and Foundayo are both approved in the US and in the UK.
Can I get the new weight loss pills on the NHS?
No. Neither pill is available on the NHS yet, and both wait on a NICE evaluation.
When will CagriSema be available?
The FDA decision is expected in the fourth quarter of 2026. If it is approved, the US launch is planned for early 2027.
Do I need an empty stomach for Foundayo?
No. Foundayo can be taken with or without food. The Wegovy pill needs an empty stomach.
What if I miss a day on the new pills?
For the Wegovy pill, skip the dose and take the next one the next day. For Foundayo, take it as soon as you can, and never double the next dose.
Keep reading
Weight loss injection prices in the UK
This page follows the official FDA, MHRA, EMA and Novo Nordisk sources and is updated when a new approval is announced. See how we check our pages.
Update log
: First published.
Sources
FDA, FDA approves Foundayo (press announcement, April 1, 2026).
Eli Lilly, Foundayo US prescribing information.
Novo Nordisk, Wegovy pill FDA approval (December 22, 2025) and Wegovy tablets US prescribing information.
MHRA, first GLP-1 tablet for weight loss approved in the UK and orforglipron authorisation.
European Medicines Agency, Foundayo.
Novo Nordisk, CagriSema company announcement.
GLP1 Note is an independent information site. Which medicine suits you is for your prescriber to decide.